| Clinical data | |
|---|---|
| Trade names | Tretten, NovoThirteen |
| AHFS/Drugs.com | Monograph |
| License data | |
| Pregnancy category |
|
| Routes of administration | Injection |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEMBL | |
Catridecacog, sold under the brand nameTretten in the US andNovoThirteen in the EU[1]) is a class ofrecombinantfactor XIII A-subunit basedbiopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind ofFactor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S.Food and Drug Administration (FDA) for this use in the US in 2014.[2] It was brought to market byNovo Nordisk.[1]
CNDO-210 and Catridecacog were discontinued due to safety concerns and lack of efficacy, respectively.
 | Thisdrug article relating to theblood andblood forming organs is astub. You can help Wikipedia byexpanding it. |
